{"id":"W2147859079","doi":"10.1200/jco.2006.05.9212","title":"Phase II Trial Evaluating the Palliative Benefit of Second-Line Zoledronic Acid in Breast Cancer Patients With Either a Skeletal-Related Event or Progressive Bone Metastases Despite First-Line Bisphosphonate Therapy","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bone health and treatments","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Dairy Farmers of Canada","keywords":"Medicine; Zoledronic acid; Bisphosphonate; N-terminal telopeptide; Palliative care; Breast cancer; Bone pain; Internal medicine; Urology; Bone remodeling; Oncology; Cancer; Osteoporosis","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001080339,0.0007937222,0.00168568,0.0002242256,0.0002719059,0.0006674579,0.0005148145,0.001044643,0.00380292],"category_scores_gemma":[0.001073351,0.000338119,0.0009912938,0.0002220743,0.0005159496,0.0003774677,0.0002383594,0.001846979,0.0005083411],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004254591,"about_ca_system_score_gemma":0.001263641,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004211609,"about_ca_topic_score_gemma":0.001445138,"domain_scores_codex":[0.9996703,0.0001932093,0.00001788495,0.0000373103,0.00003143029,0.00004994269],"domain_scores_gemma":[0.9991228,0.0002466907,0.0001981733,0.00004878566,0.00004637365,0.0003371844],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9054266,0.03153327,0.007707575,0.0007164117,0.001087044,0.0001903346,0.0001402218,0.001035921,0.01528187,0.0001068804,0.0008188587,0.03595496],"study_design_scores_gemma":[0.6654065,0.3247246,0.007423117,0.00002108548,0.0002531179,0.0001220072,0.00002436665,0.0004349232,0.0009628491,0.00004675548,0.0005725106,0.000008138556],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956198,0.001343956,0.000214099,0.0002324615,0.00007996436,0.00153654,0.0003354019,0.00002110586,0.000616616],"genre_scores_gemma":[0.9939407,0.000968614,0.0006959464,0.0005484637,0.0001813782,0.001868916,0.0008262786,0.000005364805,0.0009644058],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00380292,"threshold_uncertainty_score":0.01272207,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09509900927046033,"score_gpt":0.4882822545423567,"score_spread":0.3931832452718964,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}